Annals of Oncology Advance Access published online on June 9, 2005
Annals of Oncology, doi:10.1093/annonc/mdi271
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany Department of Nuclear Medicine, University Hospital Freiburg, Freiburg, Germany
* To whom correspondence should be addressed. Background: The aim of this study was to evaluate the accuracy of computed tomography (CT) and [18F]fluoro-deoxy-d-glucose positron emission tomography (FDG-PET) for prediction of progression-free survival of Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL) patients after completion of therapy. Patients and methods: CT and FDG-PET were performed in 40 HD, 17 indolent NHL and 44 aggressive NHL patients (29 women, 72 men; aged 41±14 years) in a median of 2 months after therapy. Progression-free survival was evaluated using the Kaplan-Meier method. Independent prognostic factors were identified by means of Cox proportional hazards model. Results: CT imaging results were progressive disease (PD) in five, stable disease (SD) in 57, and partial response (PR) or complete remission (CR) in 39 patients. FDG-PET suggested residual lymphoma in 24 patients. Three-year progression-free survival rates after exclusion of five PD patients were: 100% (PET negative; CT: PR or CR), 81% (PET negative; CT: SD), 21% (PET positive; CT: SD) and 0% (PET positive; CT: PR). FDG-PET (P<0.0001) and bulky disease (P <0.05) were identified as independent prognostic variables. Conclusions: Among lymphoma patients with PR and SD on CT, FDG-PET discriminated those destined to progress into a low risk of
Received January 28, 2005
Revised April 4, 2005
Accepted April 13, 2005
Original article
Computed tomography and 18F-FDG positron emission tomography for therapy control of Hodgkin's and non-Hodgkin's lymphoma patients: when do we really need FDG-PET?
2 Department of Nuclear Medicine, University Hospital Freiburg, Freiburg, Germany
3 Department of Diagnostic Radiology, University Hospital Freiburg, Freiburg, Germany
4 Department of Hematology & Oncology, University Hospital Freiburg, Freiburg, Germany
M. J. Reinhardt, E-mail: michael.reinhardt{at}ukb.uni-bonn.de
Abstract 
20% and a high risk for recurrence of 
80%.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  T. C. Kwee, R. M. Kwee, and R. A. J. Nievelstein Imaging in staging of malignant lymphoma: a systematic review Blood, January 15, 2008; 111(2): 504 - 516. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. I. Lee, A. Saokar, K. J. Dreyer, J. B. Weilburg, J. H. Thrall, and P. F. Hahn Does Radiologist Recommendation for Follow-up with the Same Imaging Modality Contribute Substantially to High-Cost Imaging Volume? Radiology, March 1, 2007; 242(3): 857 - 864. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. L. Kasamon, R. J. Jones, and R. L. Wahl Integrating PET and PET/CT into the Risk-Adapted Therapy of Lymphoma J. Nucl. Med., January 1, 2007; 48(1_suppl): 19S - 27S. [Abstract] [Full Text] [PDF]
|
|